Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

Healthcare Industrials Auto Parts Diversified Industrials
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the... see more

Recent & Breaking News (TSX:HLS)

HLS Therapeutics Confirms Annual Shareholders' Meeting

Canada NewsWire June 10, 2020

HLS Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Canada NewsWire June 1, 2020

HLS Therapeutics to Become Distributor of the Saladax MyCare(TM) Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents

Canada NewsWire June 1, 2020

HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19

Canada NewsWire May 21, 2020

HLS Therapeutics Announces Q1 2020 Financial Results

Canada NewsWire May 7, 2020

HLS Therapeutics to Host Q1 2020 Financial Results Conference Call

Canada NewsWire April 30, 2020

Appreciated Media Announces Name Change, New Ticker Symbol and Director Appointment

Newsfile April 1, 2020

HLS Therapeutics Comments on U.S. District Court Decision on Amarin Patents

Canada NewsWire March 31, 2020

HLS Therapeutics Announces Fourth Quarter and Fiscal 2019 Financial Results

Canada NewsWire March 19, 2020

HLS Therapeutics to Host Q4 and Fiscal 2019 Financial Results Conference Call

Canada NewsWire February 27, 2020

HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)

Canada NewsWire January 28, 2020

HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada

Canada NewsWire January 23, 2020

IIROC Trade Resumption - HLS

Canada NewsWire January 7, 2020

HLS Therapeutics Announces 8 Years of Data Protection for Vascepa®

Canada NewsWire January 6, 2020

IIROC Trading Halt - HLS

Canada NewsWire January 6, 2020

IIROC Trade Resumption - HLS

Canada NewsWire December 31, 2019

HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events

Canada NewsWire December 31, 2019

IIROC Trading Halt - HLS

Canada NewsWire December 31, 2019

HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa

Canada NewsWire November 15, 2019

HLS Therapeutics Announces Q3 2019 Financial Results

Canada NewsWire November 7, 2019